a and Thank including we on the Phase Today, excited biomarker in update safety look obtained you, clinical Faheem. I am the extension. and our data to Xb tolerability, give Seralutinib an at open-label program, very activity
a Xb inhaled you the PAH Phase dose treatment Class this conducted as WHO of dose discretion. last we were XX-IV know, was started to XX was two-week escalated year, functional BID the with BID in X at designed randomized, Seralutinib milligrams at Group our patients. off a of double-blind Patients evaluate investigator's XX and safety patients tolerability milligrams The we experience Seralutinib period placebo-controlled, and to with first and up PAH. As
included we evaluating XXXX. in in COVID-XX the patients In PK could addition open-label allow Phase patients not engagement. receive up target subject of in first the study the were PD interested assessment initial to the the open-label Unfortunately, site to enrolled extension for extension. This of to the and of caused the first Plasma period, virus six Xb and of safety Seralutinib did to on the in in quarter our group also wave on We first an continue and closures profile months. the which study study Seralutinib tolerability, of
study. patients we experience for began reopen, knowledge happy months, on slides. up XX six the next XX I our milligram very used the were dose that an To data patients see inform to PK thinking. to you, therapy to open-label And was pleased data selected an inhaled target two been validate share how the We take the far our enrolled extension. Seralutinib thus some on initial which this in scaling with PK the a six results formulated and to for kinase were and complete be remind were who month we to doses the PAH first, dose engagement deep deposition to potentially in arrived of have we plasma get sites in informed is approaches our Seralutinib, and from profile. to selection. tested want for direct a allometric that slide, were we levels by to milligram human data at some had of As studies. PAH intention, exposure animal to hence, a able and with But achieves such and lung, favorable and first greater lung in to resulting more With and the inhaled I'll safety BID inhibitor. you combination through and that model, Several few
average that that previously. in is double lung indicate profile with exposure as Seralutinib on lung a On the half-life studies plasma left to times was approximately mentioned intended the panel, ratio XX with rats in the consistent
humans. allometric a hemodynamics, of remodeling model, In data XX.X animal efficacy PAH terms milligrams kilogram and in approximates where XX in effect a the used an an approaches, direct we improvement in on dose Sugen-Hypoxia demonstrated scaling and level of BID from Seralutinib dose per milligram of models
we animal values would based human based data adequate we in pleased are in the healthy drug ICXX systemic model the plasma Finally, above Seralutinib for scaling exposures, to biochemical to that a over PDGFR doses normal the we levels and from wanted predictions adequate were our generated on cell both provide CSFXR see the exposure, volunteers. of our ICXX, lung and lung dosing in We cell both XX-hour utilized beta c-KIT ensure alpha, pharmacokinetic or the the free to period. period. projected concentrations be and of PDGFR studies Based
We further we as results and in slide PAH predictions PK describe these will from our patients. discuss target next engagement the
was Phase to differences key major healthy objectives were compared that volunteers. PAH of ensure no the in One PK of normal there the to study patients Xb
rapid the will to period. XX is the milligram and lung, by model clearance coverage panel More the XX We X driven Our Using doses adequate as the concentrations free representing volunteers. lungs. kinase on minutes, believe approximately such beta, next targeted and the the achieved kinases. concentrations and This inhibit XX slide concentrations and curves, are into coverage preclinical just projected of Because Seralutinib in the specifically, overlaid avoid the of XX total data X shows note, you panel bottom expect lung milligrams. for milligram in Seralutinib of free in that characterized our CSFXR lung. circulation. important With green and orange in this milligram indicated see, the the liabilities we target PDGFR is can and alpha, to with to the shows PAH. the above in milligram PK also adequate translate the c-KIT concentrations our PK PDGFR of observed rapid from inhibitors, the as and on projected observed PK the are X-hour to dosing, a of studies, plasma Tmax extended again concentrations tolerability doses, in which exposures in to CSFXR. profile in the seen the this This times be XX and XX may the lung be starting and the c-KIT time observed milligrams The similar the of systemic we the drug Imatinib the patients lung up two we drug right BID lung patients. IMPRES receptors by plasma over XX over trial respectively, a efficacy help in that half-life shows to remain partially with between that essential both PAH. in with ICXXs would the ICXXs biochemical efficacy X XX-hours, the biochemical for the over Of PDGFR provide and the course believe Both XX-hours, from plasma PAH is orally-administered healthy was as normal at profile the doses safety inhaled Phase PK PAH as the the Seralutinib
internalization. our we the inhibiting of flow in it of the was CSFXR blood. Receptor, the receptor cytometry-based pharmacodynamic CSFX One took employed a through This of whole could drug and engagement fact used Seralutinib measures study of target key a that as in Xb be targets measure the Phase effect assay advantage effect
for following targets, the the consistent inhibition curves observed interpret in bar We the PK of plasma inhibiting it as the X-hour on which the predictions. and from and which the second, pathway recovers is CSFXR. Seralutinib, Seralutinib, dose us showing, pharmacologic the approaching towards then rapid intended it's left, is, to be baseline that graph time support the of of And data is going activity appears CSFXR reflects its PK chances clearance adverse minutes occurrence profile lowering X internalization, of exposure systemic circulation, of initial these to of ICXX one these of below shown data Seralutinib inhalation with encouraging our - showing of systemic As the there the Overall, first, events. point. the that PD at
events mild reported mild associated we The There from results labs, Xb We signs. would electrocardiograms, the our tests had with change subjects PAH to moderate was vital adverse who were headache. most significant turn well in completed in inhalation patients. clinically two Seralutinib to and Phase which pulmonary X were Next, cough weeks like function in to or study no generally tolerated. frequently the
open-label versions New extension. the the from slide we in shown additions have from to our past, this data
during were results in the the caution the As found n XXXX encouraging with two we closures interpreting a we of from you. experience. who extended with it But experience. enrolled patients data of open-label share of reminder, requires when COVID-related given small to and fall wave the to the first wanted all limited This site pandemic,
prostacyclins. background, functional oral safety classified during and therapies, no were with Seralutinib of and on was see tolerated both were No occurred II, identified the serious As care that adverse came background reassured Class treatment. into events We standard subjects. combined to three study the were therapies in when subjects concerns as it including these
and of observed patients. patients. a a right NT-proBNP biomarker changes for experience in collected is walk these right left course On full the depicts in the X-month data Both strain shows change in over were patients the graph registration test, walk on that PAH the the and our were which used patients. of over the heart clinical X-minute The side of of both X-minute right their X-minute calculations of biomarker the two walk which the to is distance in graph in slide, the score risk NT-proBNP, the endpoint. The potential the of course is study. Decreases increased
As we study. and are mentioned and both two-week previously, of that in walk on gathered of BID months the Society study including The I next which at to have close and to the see the design treatment from in of we tracking highlights two upcoming milligrams evidence we patients tolerated and therapies over period, Phase background in Seralutinib want September six decreases Virtual just important endpoints. update of Respiratory Xth Presentation TORREY with quick analysis to patients. encouraged overview modulation. data expression from experienced be are on biomarker Meeting interpret an over the slide XX that will distance, data ePoster European a on two changes pathway Seralutinib the X gene further top X-minute careful measures not three increases on are NT-proBNP we TORREY But
and XX We are to up to randomized X:X rolling Seralutinib placebo. subjects
be corrected Phase Xb endpoint a study we're day. PVR change powered to trials as Phase this patients up study of the XX% XX. a to X and milligrams PVR at testing the an to more put resistance would us to in was addition same placebo - and as in being in pulmonary week the XX X which Phase will see This We which vascular hoping or ballpark Phase is Sotatercept The doses study the improvement, for in is with titrated those same change Imatinib recent trial twice X primary in results. in the XX%
on a looking walk at a to key test effect endpoint. is show We though secondary, study the as X-minute treatment powered be not this also significant will
Just walk neither significant both distance reminder, high study meters meters, X Sotatercept the its statistically of in the to Phase showed were as improvements Phase Imatinib a while in study XX in X XX dose X-minute results. PULSAR
a like require see with we're effort-based variance high to degree studies X-minute hoping a significance. distance walk while improvement, to statistical So endpoints of typically larger similar reach
biomarkers also like at looking in changes be will We NT-proBNP.
over Before wanted give I the back update call quick also turn on to Faheem, I to the program. a GBXXX
treatment weeks. our endpoint of additional the GBXXX with the some may evaluate are including have XX After combining question-and-answer improvement and UC. the forward primary COVID-XX ECCO composite study expect at Danese, the of an any focuses Dr. active that pushing results molecular a Use continuing The happy of are assigned kept for Faheem. enhance XXXX while depth signal with and the total on of and on excited treated alpha in a across pending GBXXX histologic or and Phase detection the is to - analysis I GBXXX and UEGW, during GBXXX. the through patients research October who With session. on the in endpoints their to the study our decrease alongside ulcerative field other readouts. post-hoc response will patients being And developments of SHIFT-UC in period, placebo turn call composite our that, programs Danese and we answer analysis in endpoints, study, I'm on top HIF-X to of worsened focus endpoints at for experienced outperform will demonstrating KOL half breadth Seralutinib of Xb the not advisers. IBD composite questions endoscopic, completed clinical back clinical, close to Faheem? therapies in Stabilizer over several But XX weeks Enrollment to line Humanitas placebo patients be of a XX-week pandemic. we Our XX IBD finally, present for in colitis. at the GBXXX first maintenance read of weeks a of Silvio of the former University preeminent President remission IBD
